FDA Expands Label for CVRx Barostim System in HF FDA Expands Label for CVRx Barostim System in HF

The Barostim neuromodulation system is now indicated in NYHA class III or class II HF despite guideline-directed medical therapies, with LVEF ≤ 35% and NT-proBNP

Source: Medscape Cardiology Headlines - December 27, 2023 Category: Cardiology Tags: Cardiology Source Type: news